Design and synthesis of novel α(1a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series

Journal of Medicinal Chemistry

Volumn 42, Issue 23, 1999, Pages 4804-4813

  Wong, Wai C ^a,c   Sun, Wanying ^a   Lagu, Bharat ^a   Tian, Dake ^a   Marzabadi, Mohammad R ^a   Zhang, Fengqi ^a   Nagarathnam, Dhanapalan ^a   Miao, Shou W ^a   Wetzel, John M ^a   Peng, Jian ^a   Forray, Carlos ^a   Chang, Raymond S L ^b   Chen, Tsing B ^b   Ransom, Richard ^b   O'Malley, Stacey ^b   Broten, Theodore P ^b   Kling, Paul ^b   Vyas, Kamlesh P ^b   Zhang, Kanyin ^b   Gluchowski, Charles ^a  

^a H LUNDBECK A S   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 [4 (2 AMINOCARBONYL)PHENYLPIPERAZIN 1 YL] PENT 1 YL] 6 (3,4 DIFLUOROPHENYL) 1,6 DIHYDRO 5 METHOXYCARBONYL 2,4 DIMETHYLPYRIMIDINE; 6 (3,4 DIFLUOROPHENYL) 1,6 DIHYDRO 5 METHOXYCARBONYL 2,4 DIMETHYL 1 (5 (4 (2 METHYLPHENYL) 4 (4 METHYLPHENYL)PIPERIDIN 1 YL)PENT 1 YL)PYRIMIDINE; 6 (3,4 DIFLUOROPHENYL) 1,6 DIHYDRO 5 METHOXYCARBONYL 2,4 DIMETHYL 1 (5 (4,4 DIPHENYLPIPERIDIN 1 YL)PENT 1 YL)PYRIMIDINE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIMIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DOG; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; DOGS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; PROSTATE; PYRIMIDINES; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032720792     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902032     Document Type: Article

References (20)

1. Kirby, R. S.; Christmas, T. J. Benign Prostatic Hyperplasia; Gower Medical Publishing: London, England, 1993; p 1.
2. 1-Adrenoceptor Antagonists as Treatments for Benign Prostatic Hyperplasia. Exp. Opin. Invest. Drugs 1995, 4(10), 915-923.
3. 1c Subtype. Mol. Pharmacol. 1994, 45, 703-708.
4. 2+ Channel Antagonist Niguldipine. J. Med. Chem. 1995, 38, 1579-1581.
5. 1a. Adrenoceptor-Selective Antagonist That Inhibits Phenylephrine-Induced Contraction of the Human Prostate. J. Med. Chem. 1998, 41, 2643-2650.
6. 1a Adrenoceptor Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia. J. Med. Chem. 1998, 41, 5320-5333.
7. 1a Adrenoceptor-Selective Antagonists. 1. Structure-Activity Relationships of Dihydropyrimidinones. J. Med. Chem. 1999, 42, 4764-4777.
8. 1a Adrenoceptor-Selective Antagonists. 2. Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety. J. Med. Chem. 1998, 42, 4778-4793.
9. Cho, H.; Shima, K.; Hayashimatsu, M.; Ohnaka, Y.; Mizuno, A.; Takeuchi, Y. Synthesis of Novel Dihydropyrimidines and Tetrahydropyrimidines. J. Org. Chem. 1985, 50, 4227-4230.
10. Thurkauf, A.; Hillery, P.; Jacobson, A. E.; Rice, K. C. An Efficient Synthesis of Optically Pure (S)-(-)-3-Methylcyclohexanone. J. Org. Chem. 1987, 52, 5466-5467.
11. Moore, W. M.; Webber, R. K.; Fok, K. F.; Jerome, G. M.; Kornmeier, C. M.; Tjoeng, F. S.; Currie, M. G. Inhibitors of Human Nitric Oxide Synthase Isoforms with The Carbamidine Moiety as A Common Structural Element. Bioorg. Med. Chem. 1996, 4, 1559-1564.
12. Smith, A. P.; Lee, N. M.; Loh, H. H. In Principles of Pharmacology; Munson, P. L., Ed.; Chapman and Hall: New York; pp 399-416.
13. The Merck Index; Budavari, S., Ed.; Merck & Co.: Rahway, NJ, 1989; p 5734.
14. 1a Adrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites Using Phenylpiperazines in Side Chains. J. Med. Chem. 1999, 42, 4794-4803.
15. Piascik, M. T.; Guarino, R. D.; Smith, M. S.; Soltis, E. E.; Saussy, S. S.; Perez, D. M. The Specific Contribution of the Novel alpha-1D Adrenoceptor to the Contraction of Vascular Smooth Muscle. J. Pharmacol. Exp. Ther. 1995, 275, 1583-1589.
16. Kenny, B. A.; Chalmers, D. H.; Philpott, P. C.; Naylor, A. M. Characterization of an Alpha-1D Adrenoceptor Mediating the Contractile Response of Rat Aorta to Noradrenaline. Br. J. Pharmacol. 1995, 115, 981-986.
17. Muramatsu, I.; Murata, S.; Isaka, H.; Piao, L.; J.; Zhu, J.; Suzuki, F.; Miyamoto, S.; Oshita, M.; Watanabe, Y.; Tanigichi, T. Alpha-1 adrenoceptor subtypes and two receptor systems in vascular tissues. Life Sci. 1998, 62, 1461-1465.
18. Muramatsu, I.; Oshita, M.; Ohmura, T.; Kigoshi, S.; Akino, H.; Gobra, M.; Okada, K. Pharmacological Characterization of Alpha-1A Adrenoceptor Subtypes in the Human Prostate: Functional and Binding Studies. Br. J. Urol. 1994, 74, 572-578.
19. Ford, A. P.; Arredondo, N. F.; Blue, D. R. J.; Bonhaus, D. W.; Jasper, J.; Kava, M. S.; Lesnick, J.; Pfister, J. R.; Shieh, I. A.; Vimont, R. L.; Williams, T. J.; McNeal, J. E.; Stamey, T. A.; Clarke, D. E. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)-ethyl]-5-chloro-α,α-dimethyl-1H- indole-3-ethanamine hydrochloride), a Selective Alpha-1A Adrenoceptor Antagonist, Displays Low Affinity for FunctionalAlpha-1 Adrenoceptors in Human Prostate: Implications for Adrenoceptor Classification. Mol. Pharmacol. 1996, 49, 209-215.
20. Daniels, D. V.; Gever, J. R.; Jasper, J. R.; Kava, M. S.; Lesnick, J. D.; Melloy, T. D.; Stephan, G.; Williams, T. J.; Clarke, D. E.; Chang, D. J.; Ford, A. P. Human cloned alpha1A-adrenoceptor isoforms display alphalL-adrenoceptor pharmacology in functional studies. Eur. J. Pharmacol. 1999, 370, 337-343.